Acorda Therapeutics has filed a patent for a pharmaceutical composition containing aminopyridine dispersed in a release matrix. The composition can be formulated into a stable, sustained-release oral dosage formulation, providing a therapeutically effective plasma level of the aminopyridine for at least 12 hours. The patent aims to treat various neurological diseases. GlobalData’s report on Acorda Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Acorda Therapeutics, human telomerase RT biomarker was a key innovation area identified from patents. Acorda Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for sustained-release oral dosage formulation
A recently filed patent (Publication Number: US20230133230A1) describes a method for treating neurological disorders using a specific dosing regimen of an aminopyridine compound. The method involves administering the aminopyridine on a dosing regimen that achieves a specific ratio of maximum concentration (Cmax) to trough concentration (Ct) in the body, as well as a specific steady-state concentration (CavSS).
The patent claims that the in vivo Cmax:Ct ratio should be between 1.0 and 3.5, and the CavSS should be between about 15 ng/ml and about 35 ng/ml. Additionally, the patent suggests that a Cmax:Ct ratio of about 1.5 to about 3.0 or about 2.0 to about 3.0 may be particularly effective.
The method is intended for the treatment of various neurological disorders, including spinal cord injury, Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Specifically, the patent mentions spinal cord injury and multiple sclerosis as examples of neurological disorders that can be treated using this method.
The dosing regimen described in the patent involves administering the aminopyridine compound in the form of a tablet twice daily. The patent further specifies that the twice daily administration should be done every twelve hours.
The aminopyridine compound mentioned in the patent is specifically identified as 4-aminopyridine.
Overall, this patent describes a method for treating neurological disorders by administering an aminopyridine compound on a specific dosing regimen that achieves a specific ratio of Cmax to Ct and a specific steady-state concentration. The method is applicable to various neurological disorders, including spinal cord injury and multiple sclerosis. The dosing regimen involves twice daily administration of a tablet, with a twelve-hour interval between doses. The specific aminopyridine compound mentioned in the patent is 4-aminopyridine.
To know more about GlobalData’s detailed insights on Acorda Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
